Novel therapeutic agents in ovarian cancer.

摘要: Abstract Aims Epithelial ovarian cancer is responsible for 4% of all deaths in women, and the five-year overall survival patients with advanced disease 30–40%. Treatment currently comprises a combination surgery chemotherapy carboplatin paclitaxel. The main reason treatment failure that majority present disease, current drugs are unable to effect cure even chemosensitive patients. This article systematically reviews novel therapeutic strategies have been evaluated last 5 years. Methods Pubmed ( http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed ) American Society Clinical Oncology Annual conference abstracts were searched using terms “(phase I OR phase II III 1 2 3) AND (ovary ovarian) (cancer carcinoma)” from January 2000 May 2005 identify studies potential inclusion this review. Reviews therapies also used additional clinical trials. Findings A wide range being cancer. These include cytotoxics, small molecule inhibitors, monoclonal antibodies, gene therapy immuno-therapy strategies. rationale development these agents includes enhancement efficacy by targeting biological pathways, re-sensitisation existing drugs, simplification drug administration and/or reduction drug-toxicity. Conclusions Current developments result substantial improvements outlook women